The short version:
GLP-1 medications (Ozempic, Wegovy, Zepbound, Mounjaro) work by significantly suppressing appetite and slowing digestion — which is exactly why they're so effective for weight loss, and exactly why they create real, documented gaps most people aren't warned about. A 2026 review covering over 480,000 adults found meaningful rates of vitamin D, iron, B12, and thiamine deficiency in GLP-1 users, and body-composition studies show 25-45% of the weight lost on these medications can come from lean muscle, not just fat. None of this means don't take them — it means eating and supplementing deliberately matters more on a GLP-1, not less. Here's what the research actually shows, and a practical protocol to protect against it.
🎙️ Prefer to listen?
AI-generated audio overview — 18 min
🎙️ Audio overview generated with Google NotebookLM. Full written article below.
GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — work by mimicking a gut hormone that signals fullness to the brain and slows how quickly food leaves the stomach. That's the entire mechanism behind their effectiveness: people simply eat meaningfully less, often without much conscious effort.
The problem is that most people's diets weren't optimized to begin with, and cutting total food intake by 20-30% doesn't discriminate between excess calories and the vitamins, minerals, and protein that were already marginal. Delayed gastric emptying — the same mechanism responsible for the appetite suppression — can also impair how efficiently the body absorbs certain nutrients, particularly fat-soluble vitamins.
None of this is a reason to avoid these medications, which have genuinely transformed outcomes for millions of people with obesity and type 2 diabetes. It's a reason to treat nutrition as an active, deliberate part of GLP-1 treatment rather than an afterthought — which, based on the research below, is often exactly what's missing from how these medications get prescribed and used.
This isn't a hypothetical concern — it's now been studied directly, and the numbers are large enough to take seriously.
A 2026 narrative review pooling six studies covering over 480,000 adults on GLP-1 receptor agonist therapy found vitamin D deficiency in 7.5% of users at 6 months, rising to 13.6% at 12 months. Iron depletion was also frequent, and separate dietary analyses found most GLP-1 users failed to meet recommended daily intakes for vitamin D, iron, calcium, and protein.
The same body of research has also identified deficiencies in vitamin B12 and thiamine (vitamin B1), with case reports linking GLP-1 use to severe thiamine deficiency, including rare cases of Wernicke encephalopathy — a serious neurological condition. These severe cases are uncommon, but they illustrate that reduced intake on a GLP-1 isn't a minor footnote; it can become a real medical issue if nutrition isn't actively managed.
A body-composition substudy of the SURMOUNT-1 tirzepatide trial found that of the total weight lost at 72 weeks, roughly 75% was fat mass and 25% was lean mass — a meaningful amount of muscle loss alongside the fat loss. An earlier body-composition analysis of the STEP 1 semaglutide trial found a similar pattern: substantial total lean mass reduction alongside fat loss, even as the proportion of lean mass relative to total body weight actually improved.
It's worth noting this isn't necessarily unique to GLP-1s specifically — some research suggests this degree of lean mass loss is largely proportional to the amount and speed of any significant weight loss, rather than a distinct drug effect. But because GLP-1-driven weight loss can be faster and larger than most people achieve through diet alone, the absolute amount of muscle at risk is often larger too — which is exactly why this deserves direct attention rather than being left to chance.
A controlled trial found that muscle protein synthesis over a 12-hour recovery period was maximized with roughly 20g of high-quality protein spread across four evenly-timed doses, rather than the same total protein concentrated into fewer, larger meals. This matters directly for GLP-1 users: appetite suppression often means people eat one small meal and effectively skip the others, which is close to the worst-case pattern for preserving muscle even if total daily protein looks adequate on paper.
None of this is a reason to be afraid of these medications — it's a reason to be deliberate about nutrition while using them, which is a very solvable problem with the right approach.
If eating enough protein at meals feels genuinely difficult due to appetite suppression, that's worth flagging to your prescriber directly — dose and timing adjustments are a normal part of managing these medications well.
GLP-1 medications work precisely because they meaningfully reduce food intake — and that same mechanism creates real, well-documented risks for micronutrient deficiency and muscle loss that most people aren't warned about clearly enough. A 2026 review of over 480,000 GLP-1 users found meaningful rates of vitamin D, iron, B12, and thiamine deficiency, and body-composition trials show a real share of weight lost on these medications is muscle, not fat.
The honest fix isn't complicated: prioritize protein at every meal, keep resistance training in the routine, and ask for periodic bloodwork rather than guessing. That combination — not a "GLP-1 support" gummy — is what the actual research supports.
1. Urbina, E.M., et al. (2026). Micronutrient and nutritional deficiencies associated with GLP-1 receptor agonist therapy: a narrative review. Clinical Obesity, 16(1), e70070.
2. Look, M., et al. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism.
3. Wilding, J.P.H., Batterham, R.L., Calanna, S., et al. (2021). Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. Journal of the Endocrine Society, 5(Suppl 1), A16–A17.
4. Areta, J.L., Burke, L.M., Ross, M.L., et al. (2013). Timing and distribution of protein ingestion during prolonged recovery from resistance exercise alters myofibrillar protein synthesis. The Journal of Physiology, 591(9), 2319–2331.
This article reflects general research on GLP-1 receptor agonist therapy. It is not personalized medical advice. Always consult the physician managing your treatment before starting any new supplement or changing your nutrition plan.